Dr. Parvez Mantry, MD

Medicare patients and services

Medicare patients, 2024

326

Services billed

705

Patients’ average age

70

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 16 companies reported 261 payments worth $302,443 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 11 industry-funded studies in 2025, from 7 companies. The companies reported $569,294 in research payments for these studies, mostly to the institutions running them.

• A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC
  Genentech, Inc.
• Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements
  Taiho Oncology, Inc.
• A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alco…
  Intercept Pharmaceuticals, Inc.
• A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
  Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05519475
• Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
  Ipsen Bioscience Inc. · Active, not recruiting · NCT04526665
• A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
  Ipsen Bioscience Inc. · Completed · NCT06383403
• Ph iii study to evaluate the efficacy and safety of astegolimab in copd
  Genentech, Inc.
• A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
  Bausch Health US, LLC
• Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
  Intercept Pharmaceuticals, Inc.
• A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis
  Intercept Pharmaceuticals, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Gastroenterology clinicians in Dallas

• Ariel W. Aday, M.D.
• Abrar Ahmed, MD
• Amisha Ahuja, M.D.
• Sagal Ali
• Michael H. Allen, MD
• Jamil S. Alsahhar, M.D.
• Lisa C. Alvarez, M.D.
• Amin M. Amin, MB.CHB